Supplementary Figure S1.



Supplementary Figure S1. Graphical representation of the project workflow. 204 fresh-frozen uninvolved mammary gland (UM), primary tumor (PT), skin (SK) and peripheral blood (BL) samples were collected from 52 individuals diagnosed with reportedly sporadic breast cancer. Uninvolved mammary gland was sampled distant from PT site and confirmed for normal histology by pathologists. After DNA extraction SNP arrays were used to identify copy number alteration patterns (CNA) and copy number neutral loss-of-heterozygosity (LOH). Next, targeted DNA sequencing was performed to identify somatic sequence variants of moderate frequency. Duplex sequencing was used to screen for low-frequency variants of *TP53* and *PIK3CA* genes in the normal mammary gland tissue of selected individuals.

Supplementary Figure S2.



Supplementary Figure S2. Age matching and distribution in the breast cancer patient cohort and the control group. Boxplots show the total number (N) of patients, average age (AV) and age range in the healthy (blue) and breast cancer (red) groups. The difference in age between groups was tested with the Mann-Whitney U test. ns – not statistically significant.

Supplementary Figure S3.



Supplementary Figure S3. Pie charts with uninvolved margin (UM), tumor (PT) and control (Ctrl) sample proportions within clusters 1-6 identified by hierarchical clustering (Figure 1). Tissue sample counts within the identified clusters: Cluster 1 – 19 PT samples; Cluster 2 – 8 PT samples, 10 UM samples; Cluster 3 – 6 PT samples, 11 UM samples, 3 control samples; Cluster 4 – 7 PT samples, 20 UM samples, 27 control samples; Cluster 5 – 19 control samples; Cluster 6 – 3 PT samples, 2 UM sample and 1 control sample.

Supplementary Figure S4.



Supplementary Figure S4. Summary of number and size of Copy Number Alterations (CNAs) in tissues from breast cancer patients and the control cohort. Mammary gland samples from age-matched patients that underwent breast reduction surgery served as the control group (Supplementary Figure S2). CNA analysis was performed to compare the number and size of the detected changes between control samples and breast cancer patient tissues. Each data point represents calculations for a single patient. Statistical significance was tested with Wilcoxon test (p value is provided next to comparison). The median value of length size (Med) is presented as log10 (Y-axis)).

Supplementary Figure S5.

a



AKT1 **c.49G>A (p.Glu17Lys), chr14:104,780,195-104,780,2340**



Sanger sequencing:



b



***CBFB* c.207dup (p.Pro70fs) chr16:67,036,600-67,036,747**



High Resolution Melting:







c



CDH1 **c.1668_1669insT (p.K557*) chr16:68,819,302-68,819,459**



Sanger sequencing:



d



MAP3K1 c.2668del (p.Asn891fs) chr5:56,881,790-56,881,946



Sanger sequencing:



e



Sanger sequencing:



f



High Resolution Melting:







g



PIK3CA **c.1035T>A(p.Asn345Lys) chr3:179,203,686-179,203,836**



Sanger sequencing:



PIK3CA **c.1093G>A(p.Glu365Lys) chr3:179,204,458-179,204,613**



Sanger sequencing:



***PIK3CA* c.3140A>G(p.His1047Arg) chr3:179,234,222-179,234,373**



Sanger sequencing:



UM BL CTRL

***PIK3CA* c.3202dup(p.Asn1068fs) chr3:179,234,282-179,234,436**



Sanger sequencing:



UM BL CTRL

h



***RAD50* c.2165dup (p.Glu723fs) chr5:132,595,682-132,595,837**



High Resolution Melting:







i



***RB1* c.418A>G (p.Thr140Ala) chrX:124,051,245-124,051,390**



High Resolution Melting:







j



TBX3 **c.584T>C c.796_797dup (p.Ser266Ilefs) chr12:114,679,553-114,679,592**



Sanger sequencing:







k



Sanger sequencing:





***TSHR* c.253A>G (p.Ile85Val) chr14:81,068,188-81,068,338**



High Resolution Melting:







Supplementary Figure S5. Somatic DNA variants detected in the normal mammary gland samples of sporadic breast cancer patients. Upper part of the lollipop plots present predicted amino acid change caused by the detected variant. Lower part presents somatic variants detected in the breast tumor samples, reported in the COSMIC database (https://cancer.sanger.ac.uk/cosmic). Missense variants are represented by blue dots, frameshift variants by red dots and nonsense by orange dots. Lollipop plots were prepared based on images generated with the ProteinPaint application[57]. Middle panels present aligned reads from targeted DNA sequencing with marked variant reads and were prepared based on IGV (Integrative Genomics Viewer, http://www.broadinstitute.org/igv). Lower panels include variant confirmation by Sanger sequencing or High Resolution Melting (HRM). UM – uninvolved mammary gland, PT – primary tumor, BL – peripheral blood, CTRL – peripheral blood from an unrelated individual. (A) Presentation of *AKT1* c.49G>A variant. PH (Protein Kinase B-like pleckstrin homology domain), red lines within the PH domain indicate phosphoinositide binding sites; KD (Catalytic domain of the Serine/Threonine Kinase). (B) Presentation of *CBFB* c.207dup variant. CBF (Core binding factor beta subunit). (C) Presentation of *CDH1* c.1668_1669insT variant. CPD (cadherin prodomain); CAL (cadherin repeat-like domain); CRD (cadherin repeat domain); ESD (early set domain); CR (cytoplasmic region). (D) Presentation of *MAP3K1* c.2668del. STKD (Serine/Threonine protein kinase catalytic domain). (E) Presentation of *MED12* c.5983C>T variant. TMC (transcription mediator complex subunit); CBD (Catenin-binding domain). (F) Presentation of *NCOR1* c.6715C>A variant. GPS2 (G-protein pathway suppressor 2-interacting domain); SANT (SWI3, ADA2, N-CoR and TFIIIB DNA-binding domains). (G) Presentation of *PIK3CA* somatic variants: c.1035T>A, c.1093G>A, c.3140A>G and c.3203dup detected in the normal mammary gland samples. p85 (p85-binding domain); RBD (Ras-binding domain); C2 (C2 domain); AD (accessory domain); CD (catalytic domain). (H) Presentation of *RAD50* c.2165dup variant. ABC (ATP-binding cassette), ZNH (zinc hook motif). (I) Presentation of *RB1* c.418A>G variant. RBA (Retinoblastoma-associated protein A domain); RBB (Retinoblastoma-associated protein B domain); RBC (Retinoblastoma-associated protein C domain). (J) Presentation of *TBX3* c.796_797dup variant. DBD (DNA-binding domain); TBOX (T-box transcription factor domain). (K) Presentation of *TP53* c.584T>C variant. TAD1, TAD2 (transcription activation domain 1 and 2); DBD (DNA-binding domain), DNA-binding sites are marked with red lines; TD (tetramerization domain). (L) Presentation of *TSHR* c.253A>G variant. LR (leucine repeats); TM (transmembrane receptor domain).

Supplementary Figure S6.



Supplementary Figure S6. Genomic destabilization as detected in the uninvolved mammary gland sample (UM) carrying somatic *AKT1* c.49G>A (p.Glu17Lys) variant. Plots present B allele frequency (BAF) and log R ratio (LRR) per chromosome.

Supplementary Figure S7.



Supplementary Figure S7. Schematic presentation of variant detection by duplex sequencing. During library preparation each DNA fragment is ligated to adapters with α and β duplex tags and flow cell sequences 1 and 2. After amplification two types of PCR products (αβ and βα) are grouped into families. True variants that are present on both DNA strands appear in the majority (>66%) of family pair members (red). Artifactual mutations are identified after error correction when single-strand consensus sequences are obtained (brown, yellow and black). Duplex consensus sequence identifies true variants (red) by pairing the respective complementary single strand consensus sequences. This figure was prepared based on: https://commons.wikimedia.org/wiki/File:Duplex_sequencing_overview_alphabeta_fix.svg.

Supplementary Figure S8.



Supplementary Figure S8. Somatic mutations in UM samples and the hallmarks of cancer. The identified somatic variants of known breast cancer-associated genes are involved in the regulation of key processes that promote tumor growth and invasion: the hallmarks of cancer. The pie chart represents functional annotation of breast cancer-associated genes targeted by somatic mutations detected in the uninvolved mammary gland, according to the COSMIC database (https://cancer.sanger.ac.uk/cosmic) and the PANTHER classification system (http://www.pantherdb.org/).

Supplementary Figure S9.



Supplementary Figure S9. Distribution of *PIK3CA* and *TP53* variants across tissues. The variant frequency is shown for all variants detected by duplex sequencing present in primary tumor (PT), uninvolved mammary gland (UM), blood (BL) and skin (SK) samples of 4 individuals (P52, P28, P51, P10). Each bar represents normalized variant frequency per tissue estimated as the sum of all substitution types divided by the frequency of the sequenced reference alleles. The error bars are calculated as the 95% confidence intervals of a Poisson distribution.

Supplementary Figure S10.



Supplementary Figure S10. Mutational spectra of *PIK3CA* variants. The relative count per substitution type is shown for all variants detected by duplex sequencing present in primary tumor (PT), uninvolved mammary gland (UM), blood (BL) and skin (SK) samples. The relative count of 3 individuals is shown per substitution type (ordered as P51 with 84 variants in PT, 91 variants in UM, 151 variants in SK and 56 variants in BL; P28 with 70 variants in PT, 45 variants in UM, 90 variants in SK and 39 variants in BL; P10 with 41 variants in PT, 70 variants in UM, 112 variants in SK and 41 variants in BL).